TAZVERIK™ Has Received FDA Accelerated Approval for Epithelioid Sarcoma
According to a January 2020 release by Business Wire, the USFDA has awarded accelerated approval of Epizyme’s TAZVERIK™ in the treatment of advanced epithelioid sarcoma (ES). The approval was…